tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Michael Schmitz, 41 are a BUY (82%), 9 are a HOLD (18%).
Analyst Michael Schmitz, currently employed at GUGGENHEIM, carries an average stock price target met ratio of 72.58% that have a potential upside of 69.12% achieved within 748 days.
Michael Schmitz’s has documented 98 price targets and ratings displayed on 26 stocks. The coverage is on Energy, Healthcare, Financial Services sectors.
Most recent stock forecast was given on RVMD, Revolution Medicines at 28-Aug-2026.
Analyst best performing recommendations are on EQT (EQT).
The best stock recommendation documented was for EQT (EQT) at 2/28/2020. The price target of $8 was fulfilled within 14 days with a profit of $2.53 (46.25%) receiving and performance score of 33.04.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Sell Since 31-Oct-2024
$14
$-60.27 (-81.15%)
$70
1 years 11 months 21 days ago
(31-Oct-2024)
10/11 (90.91%)
$-60.27 (-81.15%)
55
Buy Since 27-Jul-2021
$74.28
$0.01 (0.01%)
$75
3 years 11 months 28 days ago
(24-Oct-2022)
7/10 (70%)
$0.38 (0.51%)
76
Hold Since 20-Apr-2021
$74
$-0.27 (-0.36%)
$72
3 years 11 months 28 days ago
(24-Oct-2022)
9/9 (100%)
$0.1 (0.14%)
48
Sell Since 19-May-2020
$74
$-0.27 (-0.36%)
$67
4 years 3 days ago
(19-Oct-2022)
11/14 (78.57%)
$0.43 (0.58%)
25
Sell Since 18-Oct-2022
$74
$-0.27 (-0.36%)
$70
4 years 4 days ago
(18-Oct-2022)
9/10 (90%)
$0.32 (0.43%)
23
Which stock is Michael Schmitz most bullish on?
What Year was the first public recommendation made by Michael Schmitz?
